Skip to content
lifestyle.serversfree.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Elicio Therapeutics Inc.
Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026
September 24, 2026
Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
August 31, 2026
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
August 24, 2026
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
August 13, 2026
Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma
August 10, 2026
Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering
July 6, 2026
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
July 2, 2026
Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes
June 29, 2026
Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer
June 17, 2026
Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer
June 15, 2026
1
2
Next Page
→